Dengue fever is the mosquito borne tropical disease caused by dengue virus which is spread by several species of Aedes aegypti type mosquito. Dengue vaccine is a vaccine which is used to prevent dengue fever in human beings. Vaccine was recommended as the only option by the World Health Organization in the countries where this disease is commonly prevailing. The global dengue vaccine market is expected to grow at a CAGR of about 18 % during the forecast period 2016-2023. Due to the increasing demand of effective drug to reduce the effect of Zika and Chikungunya viruses, a massive growth in the economy of global dengue vaccines market has been recorded. Also, the dengue vaccine currently available is used to prevent slow dengue only. Due to this, there is a large demand for best efficient drugs and vaccines for dengue. Also majority of the key market players are joining hands together to completely eradicate dengue fever from the entire world.
The key driver fuelling the growth of global dengue vaccine market is the increasing number of occurrences of dengue fever. There is large concern for increasing number of dengue cases worldwide. As per https://www.interhealthworldwide.org/, The Philippines Department of Health-Epidemiology Bureau has reported that there was 41% increase in dengue fever cases in Philippines from 01 January 2016 to 11 June 2016 as compared to the same period in 2015. Therefore dengue has become a very dangerous threat in Philippines with a rise in cases from July to November every year, 1 to 2 months after the commencement of the rainy season. According to the World Health Organization [WHO], in 2012 the number of deaths caused by dengue virus was 297, 873, and 159 per million in low income, lower-middle income and upper-middle income regions respectively. According to PAHO, WHO, there was a five-fold increase in the number of dengue cases in the America between 2003 and 2013. In the America, nearly 500 million people are at risk of getting infected by the disease. Despite the efforts done by the dengue infected countries to control the disease, dengue continues to spread due to unplanned and uncontrolled urbanization, lack of basic amenities in communities, poor environmental management, and climate change and other reasons. In the America, nearly 500 million people are at risk of contracting the disease.
Source: OBRC Analysis.
The report on global dengue vaccines market includes product type, technology type and end user.
Product Type included in dengue vaccine market report are:
- CYD-TDV (Dengvaxia )
Technology Type included in dengue vaccines market report are:
- Live attenuated vaccine
- Chimeric Live attenuated vaccine
- Subunit vaccine
- Inactivated vaccine
- Nucleic acid based vaccine
The end users of dengue vaccines include:
- Hospitals
- Government institutes
- NGO
The global dengue vaccines market report has been geographically segmented into:
- North America (U.S. & Canada)
- Asia Pacific (China, India, Japan, RoAPAC)
- Europe (UK, France, Germany, RoE)
- Rest of World
Dengue is a deadly disease which is continuously spreading over the globe. Countries such as Brazil, Singapore, India are the leading market for dengue vaccine. The revenue growth of the dengue vaccine market is due to the adoption of dengue vaccine by various countries in dengue endemic regions of Latin America and Asia Pacific and due to increase in governmental interest to deploy the dengue vaccine in public immunization programs across several countries.
Global dengue vaccine market report is segmented on the basis of product type, technology type and end users. Furthermore, on the basis of technology type, market report is segmented into live attenuated vaccine, Chimeric Live attenuated vaccine, Subunit vaccine, inactivated vaccine, and Nucleic acid based vaccine. The end users of dengue vaccines include Hospitals, Government institutes and NGO. Among these segments, The Government Institutes segment is expected to lead the global dengue vaccine market in revenue terms and it is going to continue its dominance throughout the forecast period. The Government Institutes segment is expected to account for 50% revenue share in 2017 and is expected to account for 51.9% revenue share by the end of 2023. In terms of market value, the Hospitals segment is expected to grow at a CAGR of 17.3% during the forecast period. The NGO segment is anticipated to remain the least effective segment in the global dengue vaccine market in terms of revenue over the forecast period. The NGOs segment is estimated to hold 23% revenue share in 2017 and is expected to account for 21 % market value share by the end of 2023.
The major market players of the global dengue vaccines market are:
- SANOFI PASTEUR
- BIOLOGICAL E. LIMITED
- MERCK & CO.
- GLAXOSMITHKLINE
- PFIZER
- OTHERS
These companies using various strategies such as merger & acquisition, collaboration, partnership and product launch. Whereas, merger & acquisition is the key strategy adopted by the companies in the dengue vaccines market.
For Example; In June 2017, Sanofi Pasteur, had partnered with Ya Kun Kaya Toast to launch “Be A Wall Against Dengue” which is a disease education campaign in order to raise awareness on dengue prevention in Singapore. This was done in conjunction with ASEAN Dengue Day on 15 June 2017.
In June 2017, Takeda pharmaceutical company and Biological E. limited entered into a partnership for the development and delivery of low-cost combination vaccines.
The report covers detailed analysis of companies which comprises overview, SCOT analysis, product portfolio, strategic initiative, strategic analysis, competitive landscape and market share analysis in dengue vaccines market.
Key reason to buy the report:
- The report includes market estimation, forecast and analysis for the year 2016-2023.
- Report includes detailed analysis of different segments such as product type, technology type and end users of dengue vaccines.
- Identify and understand the strength, opportunities, challenges and threat of the dengue vaccines market.
- Covers details analysis of Porter's 5 force model and other strategic models and also covers revenues, market share analysis and competitive landscape analysis of major players of dengue vaccines market.
- Detailed analysis of various the regulatory policies which are affecting the global dengue vaccines market.
How we are different from others:
At Occam’s we provide an extensive portfolio which is comprehensive market analysis along with the market size, market share, and market segmentation. Our report on global dengue vaccines market offers detailed analysis of strategic models such as investment vs. adoption model, seesaw analysis and others strategic models. Also, the report contains the detailed analysis of application, adoption scenario and decision support for each segment. The report discusses competitive landscape of the dengue vaccines market, with giving extensive SCOT analysis of key companies.
Key findings of the global dengue vaccines market.
- The global dengue vaccine market is expected to grow at a CAGR of about 18 % during the forecast period 2016-2023.
- In 2015, the global dengue vaccines market was valued to be worth 70 million.
- Countries such as Brazil, Singapore, India are the leading market for dengue vaccine.
- The Government Institutes segment is expected to lead the global dengue vaccine market in revenue terms and it is going to continue its dominance throughout the forecast period.
- Merger & acquisition is the key strategy adopted by the companies in the dengue vaccines market.
